Capital.
Forecast.
Story.
What you allocate this year is the story your board reads next year.
This briefing tells you which capital-allocation decisions become 10x bets in medtech as AI compresses the cost stack. Read it before your peers send their version to the board.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Every CFO at a mid-sized European medtech firm has had the same Thursday morning. Four things on the screen at 8:30. The notified body queried the MDR technical file on Wednesday and moved the CE-mark window by six months, which puts your Q3 device-sale revenue at 92% of plan. Your best DACH regional sales lead took a headhunter call last week. Your Head of R&D wants €2M next quarter for clinical-evidence and regulatory-submission tooling. Your sponsor's partner forwarded a trade-press piece on AI-native competitors winning hospital tenders, with one line: curious to hear your thinking on AI and commercial productivity before Monday.
You have signed fifteen forecasts for this board. The pattern used to be simple. Hold the device-sale plan, grow service attach into the install base. The job has not changed in fifty years. The bar has risen on every measure of doing it, simultaneously, and the contradictions you have been navigating since you took the seat are suddenly re-openable.
The €2M your Head of R&D wants for clinical-evidence and regulatory-submission tooling is not a submission line. It is the largest single capital-allocation decision you will make this decade.
This is the question your chair is already asking. The briefing below is what you want in your hand before the next forecast review.
Capital Allocation. Forecast Credibility. Value-Creation Narrative.
Three questions every medtech CFO is tracking. The first is the crux. The other two are how you earn the right to answer it.
Where does the next €10M actually compound?
R&D envelope expansion, clinical-evidence and regulatory infrastructure, sales force productivity rebuild for AI-equipped hospital buyers, service and installed-base expansion, tuck-in acquisition of an AI-native evidence tool, working-capital extension on stretched hospital DSO. Today's default: budgets split along functional lines, the CFO signs the totals, authorship slides to whichever function shouts loudest.
Why did device-sale revenue print below plan, and what is the gate-plus-tender story?
Your board voted on 12% device-sale growth. Your firm is printing 4%. Your Head of FP&A cannot walk the audit committee through the account-level story. The regulatory-timing signal sits in RA correspondence. The tender-conversion signal sits in commercial CRM. The service-attach signal sits in installed-base telemetry. The HTA-evaluation signal sits in dossiers her team has never seen.
What does this firm do that compounds faster than peers?
Your board wants the strategy-day preview. Your sponsor wants the AI-and-commercial-productivity note. Your chair wants the how-we-stay-ahead answer. Three audiences, three documents, three teams, and the numbers underneath them do not match.
What you get when you download
An 11-page report for Chief Financial Officers at mid-market European medtech firms. Designed to be read in one sitting before your next forecast review.
Your industry, your finance function, and why they are one problem
What is happening in mid-market medtech as a sector. What is happening inside your capital, your forecast, your rate-card architecture, your Controller bench, and your economic thesis right now. And the intersection most CFOs have not named yet: you do not have three scorecard problems, you have one.
Four moves across capital, forecast, pricing, and narrative
Route the clinical-evidence and regulatory decision through the M&A hurdle. Rebuild the device-sale forecast as a live driver graph integrating regulatory-gate timing, tender pipeline, service attach, and installed-base telemetry. Migrate pricing from one device-sale mechanic to three. Write the economic thesis once, refresh continuously.
Five questions for your next forecast review
The clinical-evidence-and-regulatory-tooling question. The 12%-plan-4%-print question. The three-pricing-mechanics question. The three-audiences-one-thesis question. The 2031-succession-bench question. Where your finance leadership cannot agree on the answer is the conversation worth an hour on the agenda.
Calibrated for each seat at the table.